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ABSTRACT
Background.
18F-ﬂuorodeoxyglucose positron emission
tomography (FDG-PET) has been used extensively to
explore whether FDG Uptake can be used to provide
prognostic information for esophageal cancer patients. The
aim of the present review is to evaluate the literature
available to date concerning the potential prognostic value
of FDG uptake in esophageal cancer patients, in terms of
absolute pretreatment values and of decrease in FDG
uptake during or after neoadjuvant therapy.
Methods. A computer-aided search of the English lan-
guage literature concerning esophageal cancer and
standardized uptake values was performed. This search
focused on clinical studies evaluating the prognostic value
of FDG uptake as an absolute value or the decrease in FDG
uptake and using overall mortality and/or disease-related
mortality as an end point.
Results. In total, 31 studies met the predeﬁned criteria.
Two main groups were identiﬁed based on the tested
prognostic parameter: (1) FDG uptake and (2) decrease in
FDG uptake. Most studies showed that pretreatment FDG
uptake and postneoadjuvant treatment FDG uptake, as
absolute values, are predictors for survival in univariate
analysis. Moreover, early decrease in FDG uptake during
neoadjuvant therapy is predictive for response and survival
in most studies described. However, late decrease in FDG
uptake after completion of neoadjuvant therapy was pre-
dictive for pathological response and survival in only 2 of 6
studies.
Conclusions. Measuring decrease in FDG uptake early
during neoadjuvant therapy is most appealing, moreover
because the observed range of values expressed as relative
decrease to discriminate responding from nonresponding
patients is very small. At present inter-institutional com-
parison of results is difﬁcult because several different
normalization factors for FDG uptake are in use. Therefore,
more research focusing on standardization of protocols and
inter-institutional differences should be performed, before
a PET-guided algorithm can be universally advocated.
Esophageal cancer is an aggressive disease with early
dissemination. Even after potentially curative surgery,
long-term survival rates rarely exceed 35%.
1,2 In order to
improve this outcome, institutes apply neoadjuvant che-
motherapy and/or radiotherapy; however, only patients
who respond to this therapy beneﬁt.
3–7
Assessment of prognosis can inﬂuence patient manage-
ment; a diagnostic test that provides pretreatment
prognostic information will therefore have additional
value. Moreover, prediction of tumor response early, dur-
ing the neoadjuvant regimen, is of crucial importance.
18F-ﬂuorodeoxyglucose positron emission tomography
(FDG-PET) is a noninvasive imaging technique that
enables quantiﬁcation of tumor activity on the basis of
altered tissue glucose metabolism.
8–10 Many studies have
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DOI 10.1245/s10434-011-1732-1been published on the improvement of preoperative staging
of esophageal cancer with FDG-PET by detecting distant
metastases.
11–13 FDG-PET also seems to be a valuable tool
to monitor early response to neoadjuvant therapy.
14–16
Evidence for reliable and useful response measurement in
esophageal cancer patients is growing, while response
measurement is already well established in, for example,
non-small cell lung cancer and lymphoma.
17–21
Recent literature suggests that FDG-PET at time of
diagnosis might be useful for prognostication. The under-
lying idea is that the quantity of FDG activity in the tumor
correlates with viable tumor cell number and thus with
prognosis.
22–26 The most commonly applied (semi-)
quantiﬁcation parameter in clinical PET is the standardized
uptake value (SUV) of the primary tumor. SUV is deter-
mined by the ratio of activity in the region of interest
(Bq/mL) over the decay-corrected activity of FDG injected
into the patient (Bq/g).
27,28
The present review evaluates the literature available to
date concerning the potential prognostic value of FDG
uptake in esophageal cancer patients, in terms of absolute
pretreatment value and of decrease in FDG uptake during
or after neoadjuvant therapy.
LITERATURE SEARCH
A review of the English language literature concerning
esophageal cancer and standardized uptake values was
performed. A computer-aided search was performed of the
databases PubMed and Embase in January 2009. The terms
‘‘positron emission tomography,’’ ‘‘FDG-uptake,’’ ‘‘SUV,’’
and ‘‘esophageal cancer,’’ with restriction to the English
language only, were used.
29 All searches were performed
using text word or medical subject heading (MeSH).
Searches were focused on clinical studies evaluating the
prognostic value of FDG uptake as an absolute value or the
decrease in FDG uptake (during neoadjuvant therapy),
possibly in combination with other factors, and using
overall mortality and/or disease related mortality as an end
point in esophageal cancer patients. Two researchers
(J.M.T.O. and M.v.H.) read all abstracts and evaluated
whether an abstract met the predeﬁned criteria. After this
selection, all publications were retrieved as full papers and
re-evaluated for inclusion.
RESULTS
In total, 31 studies met the predeﬁned criteria.
14,16,30–59
Two main groups were identiﬁed based on the tested
prognostic parameter: (1) FDG uptake and (2) decrease in
FDG uptake. In the ﬁrst group, 15 studies described FDG
uptake measured before any form of treatment was started
(group 1A: Table 1), and 5 studies described FDG uptake
measured after neoadjuvant treatment (group 1B:
Table 2).
30–44,52–56 In the second group, 6 studies described
decrease in FDG uptake measured early during neoadju-
vant therapy (group 2A: Table 3), and also 10 studies
described decrease in FDG uptake measured after
completion of neoadjuvant therapy (group 2B:
Table 3).
14,16,38,41,42,45–51,55,57–59 Also, 9 studies described
the same cohorts of patients; however these were not
excluded.
31,32,35,36,41,42,47,49,51 Methodological aspects of
included studies are described in Tables 4, 5, and 6.
FDG Uptake as Prognostic Factor (Group 1)
Group 1A: Pretreatment FDG Uptake and Prognosis
(Table 1) In 1998 Fukunaga et al. found in 48 patients
that even though clinicopathological ﬁndings did not
correlate with FDG uptake, patients with a high SUV had
a poorer prognosis compared with those with low FDG
uptake (55% 2-year disease-free survival vs 30%).
33 This
study is limited by the lack of multivariate analysis. In
2002 Kato et al. showed that FDG uptake was associated
with depth of tumor invasion, presence of lymph node
metastases, and lymphatic vessel invasion in 32 patients.
35
The 2-year survival rate in patients with high FDG uptake
(48%) was lower than in patients with low FDG uptake
(91%). It would have been helpful if the authors had
provided 95% conﬁdence intervals for these survival rates.
In another publication on partly the same cohort, a
signiﬁcant correlation was found between FDG uptake
and Glut-1 expression; low Glut-1 expression and low FDG
uptake appeared to carry a better prognosis: these patients
showed 100% 2-year survival (n = 15).
36 Multivariate
analysis was unfortunately not performed.
Choi et al. showed in a multivariate analysis that only
PET ? lnn was an independent prognostic factor for dis-
ease-free survival.
31 In multivariate analysis for overall
survival only cTNM, pTNM, PET tumor length, and
PET ? lnn were independent predictive factors. The large
proportion of patients with squamous cell carcinomas
included in this study limits the use of these results in
western populations. In another publication on partly the
same cohort multivariate analysis showed pTNM,
PET ? lnn, VEGF expression, and intratumoral micro-
vessel density (MVD) to be independent predictors for
overall survival. A total of 7 variables were included in the
multivariate regression model, well exceeding the gener-
ally acceptable number of 1 variable per every 10 events
and thus increasing the risk of coincidental ﬁndings.
32
Hong et al. showed in 47 patients with locoregional
esophageal cancer that the number of PET abnormalities
(NPA) correlates with overall and disease-free survival in
univariate and multivariate analysis, while FDG uptake did
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3340 J. M. T. Omloo et al.not.
34 Only half of the patients underwent esophagectomy
(no explanation provided). Clinical TNM stage was not
included in this analysis to assess independent value of
NPA. Stahl et al. showed in a retrospectively analyzed
cohort of 40 patients with esophageal cancer that FDG
uptake in the primary tumor did not correlate with overall
survival.
40 The authors suggest that the reason for this
might be because they only included adenocarcinomas.
Van Westreenen et al. investigated the relation between
FDG uptake and the stage of disease and whether FDG
uptake could be used to predict resectability and survival in
40 retrospectively collected patients with any stage of
disease.
43 Patients with high FDG uptake had a worse
mean survival rate compared with patients with low FDG
uptake (9 months compared with 20 months; P = .02).
Patients eligible for resection showed a signiﬁcantly lower
FDG uptake compared with those with irresectable disease.
Cerfolio and Bryant showed in a multivariate analysis
that patients with high FDG uptake were more likely to
have poorly differentiated tumors and advanced stage using
a retrospective cohort of 89 patients.
30 Remarkably, FDG
uptake correlated better with survival than pathological
TNM stage. The 4-year survival of patients with low FDG
uptake was 89% and only 31% in patients with high FDG
uptake. It was, however, stated that many different
pathologists with unspeciﬁed experience were used for
staging the resection specimens.
Rizk et al. found that 3-year survival was 95% for
patients with low FDG uptake and 57% for patients with
high FDG uptake, in a retrospective analysis of 50 patients
with resectable adenocarcinoma of the distal esophagus.
39
The survival advantage for patients with low FDG uptake
was even seen in a subset of patients with clinically and
pathologically early-stage disease. This ﬁnding is quite
remarkable considering the range of survival in this group
of patients compared with a group of patients with all
stages of disease.
Westerterp et al. investigated biological parameters to
predict in which patients FDG-PET could be of prognostic
value, in 26 patients.
44 No association was found between
FDG uptake and angiogenic markers, hexokinase isoforms,
Ki-67 antigen expression, cleaved caspase-3, cell density,
differentiation grade, CD68, mucus, or necrosis. Glut-1
expression showed a signiﬁcant correlation with FDG
uptake. They concluded that Glut-1 may be used to select
esophageal cancer patients in whom FDG-PET is of diag-
nostic value. Even in the subgroup of patients who
underwent a microscopically radical resection a strong
association was found between SUV and survival
(P = .001).
In one of the largest available prospective studies,
Omloo et al. assessed the prognostic importance of SUV
and EUS parameters.
56 In 125 patients who underwent
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3346 J. M. T. Omloo et al.esophagectomy without neoadjuvant therapy SUV, tumor
location, EUS T-stage, EUS N-stage, and clinical stage
proved to be of prognostic signiﬁcance in univariate anal-
ysis. In multivariate analysis, however, EUS T-stage
appeared to be the only independent predictor for survival.
Cheze-Le Rest et al. investigates a total of 52 patients
with all stages of disease; performance of potentially
curative surgery, SUVmax[9 and 2 or more PET abnor-
malities were signiﬁcant prognostic predictors.
53 In
multivariate analysis, only SUVmax [9 and the presence
of FDG-positive lymph nodes were found as independent
predictors of poor outcome. Notably, 2 of 3 PET-derived
parameters were almost identical: presence of [1 FDG-
PET positive node and presence of[2 FDG-PET positive
nodes. In the largest available study Chatterton et al. aimed
to determine the impact of PET on clinical management
and prognosis in 129 potentially curable patients.
52 Sig-
niﬁcant changes in management were observed in 38% of
patients, primarily as a result of the identiﬁcation of
additional sites.
Makino et al. found SUVmax \12 and the number of
positive lymph nodes (PET ? LNN) on PET before ther-
apy to be of prognostic signiﬁcance in a retrospective
cohort of 38 patients with positive lymph nodes scheduled
to undergo neoadjuvant chemotherapy.
55 Unfortunately
only 38 of 63 patients who met the inclusion criteria were
included.
In summary, most studies (12 of 15) showed that pre-
treatment FDG uptake is a predictor for survival in
univariate analysis, whereas only 2 studies showed FDG
uptake to be a predictor of survival in multivariate analy-
sis.
30–33,35,36,39,43,44,53,55,56 More importantly, neither of the
2 largest prospective trials could prove the prognostic
signiﬁcance of FDG-PET.
52,56
Group 1B: Residual Postneoadjuvant Treatment FDG
Uptake and Prognosis (Table 2) In a prospective trial,
Swisher et al. reported postneoadjuvant treatment FDG-
PET uptake to be able to predict response, but failed to
accurately rule out microscopic residual tumor (R1
resection) in 18% of a total of 83 patients.
41 Swisher et al.
evaluated a similar cohort of patients to assess the utility of
PET, endoscopic ultrasonography (EUS), and CT to predict
pathologic response and survival.
42 FDG uptake was most
accurate to predict long-term survival after neoadjuvant
therapy. As before, they concluded that FDG uptake cannot
rule out residual disease and that esophagectomy should
remain part of the therapy. Because many of the patients in
this study also seem included in the previously described
study by Swisher et al., these reports should not be regarded
as 2 separate studies.
41
Konski et al. found a correlation between the depth of
tumorinvasion(determinedbyendoscopicultrasonography)
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Review of Potential Prognostic Value of FDG Uptake in Esophageal Cancer Patients 3347and the baseline FDG uptake in 81 patients undergoing
deﬁnitive or preoperative chemoradiotherapy.
37 Only post-
treatment FDG uptake predicted disease-free survival in the
deﬁnitive chemoradiotherapy group. The authors state to be
cautiouswhenusingposttreatmentFDGuptaketodetermine
thenecessityofsurgicalresection,asinthisgroupofpatients
no correlation between FDG uptake and disease-free sur-
vival was found. It remains unclear which variables were
used in multivariate analysis, complicating data
interpretation.
In a relatively small study Mamede et al. showed that
FDG uptake measured before treatment correlated with
clinical T stage, advanced clinical stage, tumor length, and
tumor volume as determined on PET.
38 FDG uptake
measured after treatment was the best predictor of disease
progression. The authors conclude that FDG uptake should
have a deﬁnite role in the evaluation of response to therapy
and in the prediction of progression-free survival, which
seems rather progressive considering the number of
included patients (n = 25).
Higuchi et al. showed low FDG uptake after neoadju-
vant treatment to be predictive for long-term survival
(P = .0071); SUV was measured in 29 of 50 patients who
were included.
54 Unfortunately, multivariate analysis
including histopathological response was not performed.
In summary, all 5 studies showed that FDG uptake after
neoadjuvant therapy was predictive for survival in uni-
variate analysis; however, in multivariate analysis only 1
study showed FDG uptake to be independently predictive
for survival.
37,38,41,42,54
Decrease in FDG Uptake as Prognostic Factor
(Group 2)
Group 2A: Decrease in FDG Uptake Early During
Neoadjuvant Treatment and Prognosis (Table 3) In
2001 Weber et al. evaluated in a small but well-
performed study whether reduction of FDG uptake can
predict response 14 days after start of neoadjuvant
chemotherapy.
49 A signiﬁcant difference in reduction of
FDG uptake was found between responding (-54%) and
nonresponding patients (-15%). Applying the optimal
ROC-derived cutoff value of 35% reduction as criterion for
metabolic response, FDG-PET predicted histopathological
response with a sensitivity of 93% (14 of 15 patients) and a
speciﬁcity of 95% (21 of 22). Patients without metabolic
response were characterized by signiﬁcantly shorter 2-year
overall survival (37% vs 60%, P = .04).
This same group of investigators validated the previous
ﬁndings using this deﬁnition of metabolic response, using
65 patients.
47 Metabolically responding patients showed a
high histopathologic response rate (44%) with a 3-year
survival rate of 70%. Metabolically nonresponding patients
showed a histopathologic response rate of only 5%, and a
3-year survival rate of 35% (P = .01). The authors con-
cluded that this study provides the basis for clinical trials in
which preoperative treatment is discontinued for patients
without metabolic response early in the course of therapy.
To assess the feasibility of a PET-response-guided
treatment algorithm, the same group of investigators con-
ducted a prospective single-center study, including 119
patients all of whom underwent 2 weeks of neoadjuvant
chemotherapy and subsequent evaluation.
14 After 2 weeks,
metabolic responders (FDG uptake decrease [35%) con-
tinued to receive neoadjuvant chemotherapy for 12 more
weeks; nonresponders discontinued neoadjuvant treatment
and proceeded to immediate surgery. In addition, 58% of
the metabolic responders also appeared to be histopathol-
ogical responders. Median disease-free survival in
metabolic responders was 30 months compared with
14 months in metabolic nonresponders. These results could
at least partly be explained by the fact that metabolic
responders underwent a total of 14 weeks of chemotherapy,
whereas nonresponders only had 2 weeks of chemotherapy.
In another study from this same group of investigators,
FDG-PET was performed before initiation of chemother-
apy, 14 days after the start and preoperatively in 24
patients.
51 Changes in FDG uptake at both time points were
signiﬁcantly correlated with histopathologic response, and
reduction in FDG uptake early in the course of therapy was
also signiﬁcantly correlated with survival (P = .03).
In2004Wieder etal.analyzed 38patients with squamous
cell carcinomas treated with neoadjuvant chemoradiother-
apy and subsequent esophagectomy.
50 Histopathological
responders showed a decrease of 44% in FDG uptake after
2 weeksoftherapy,comparedwith21%inhistopathological
nonresponders (P = .06). Metabolic changes were signiﬁ-
cantly correlated with survival (P = .01).
In 2006 Westerterp et al. performed FDG-PET before
start and after 14 days of neoadjuvant thermochemoradio-
therapy.
16 In histopathological responders the median
decrease in FDG uptake was 44%, compared with 15% in
nonresponders. At a cutoff value of 31% decrease in FDG
uptakecomparedwithbaseline,sensitivitytodetectresponse
was 75% with a corresponding speciﬁcity of also 75%.
In summary, all 6 of the aforementioned studies showed
that early decrease in FDG uptake is predictive for patho-
logical response. All but 1 study showed decrease in FDG
uptake also to be predictive for survival.
16 Unfortunately, 5
of 6 of these studies were performed in 1 single institute,
underlining the need for new multicenter studies to conﬁrm
these ﬁndings.
Group 2B: Decrease in FDG Uptake Postneoadjuvant
Treatment and Prognosis (Table 3) Port et al.
retrospectively reviewed the ability of FDG-PET to
3348 J. M. T. Omloo et al.predict clinical and pathological response to preoperative
chemotherapy in 62 patients.
48 Almost 60% of the patients
showed C 50% decrease in FDG uptake, showing a better
survival compared with metabolically nonresponding
patients (36 vs 18 months, P = .03). Multivariate
analysis showed metabolic response to be the only
signiﬁcant predictor for disease-free survival. Including 5
variables in a multivariate model with roughly 60 patients
and 30 events is, however, a stretch.
Makino et al. found that patients with a decrease in SUV
above the cutoff value of 70% showed signiﬁcantly better
survival.
55 Decrease in uptake in the primary tumor as well
as in lymph nodes were associated with survival.
In 2003 Downey et al. found that stratiﬁcation below or
above 60% decrease in FDG uptake leads to a 2-year
survival of 38% in metabolic nonresponders compared with
67% for metabolic responders (P = .06).
45 No details were
provided as to why only 39 of a total of 184 patients were
included in this study.
In 2006 Levine et al. evaluated a total of 64 patients who
underwent PET before the initiation of therapy and
4–6 weeks after completion of therapy.
46 A decrease in
absolute FDG uptake was predictive of histopathological
response (P = .05), not for survival.
The study of Mamede et al. found a 32% decrease in
FDG uptake to be the best cutoff value for histopatholo-
gical response with 75% sensitivity and 63% speciﬁcity
and for disease-free survival.
38
Roedl et al. found the highest accuracy to predict
response and survival using the decrease of the diameter-
SUV index, a decrease of 55% or more identiﬁed patho-
logic responders with a sensitivity of 91% and a speciﬁcity
of 93%.
58 Metabolic responders had a mean disease-free
survival of 32 months, nonresponders 16 months
(P = .001).
In another study of Roedl et al., 51 patients with ade-
nocarcinoma were studied.
57 Decrease in tumor volume
appeared to be a better predictor for response and survival
compared with decrease in SUV. The highest accuracy was
achieved using the total lesion glycolysis (calculated by
multiplying the tumor volume using the mean SUV of the
volume) to identify treatment responders.
Schmidt et al. found neither baseline nor preoperative
nor SUV reduction to correlate signiﬁcantly with response
or survival in 55 patients treated with neoadjuvant
chemoradiotherapy.
59
In summary, decrease in FDG uptake after completion
of neoadjuvant therapy was predictive for response and
survival in only 4 of 10 studies.
38,48,55,57 Remarkably, these
studies included fewer patients and showed lower per-
centages of responding patients compared with the other 6
studies. Despite some positive ﬁndings, none of these
studies suggests that these posttreatment prediction models
should have any therapeutic consequences.
DISCUSSION AND CONCLUSION
Most studies showed that pretreatment FDG uptake and
postneoadjuvant treatment FDG uptake as absolute values
are predictors for survival in univariate analysis. Moreover,
early decrease in FDG uptake during neoadjuvant therapy
is predictive for response and survival in most studies
described. However, late decrease in FDG uptake after
completion of neoadjuvant therapy was predictive for
response and survival in only 2 of 6 studies. A major dis-
advantage is that some studies included patients with a
wide range of disease (adenocarcinomas and squamous cell
carcinomas, stage I through IV) and studies used different
neoadjuvant treatment regimens. Especially those studies
that describe patients receiving radiotherapy, it is known
FDG uptake in these patients remains higher compared
with patients receiving only chemotherapy. Most impor-
tantly, all institutes used different scanners with different
protocols and used different reconstruction methods, and
these heterogeneous data made pooling of results
impossible.
Many prognostic factors, determined pretreatment and/
or posttreatment, for example, TNM stage, histopathology
results, and PET-derived parameters (including SUV,
metabolic tumor volume, and total lesion glucolysis) are
used to predict survival in esophageal cancer patients.
60 In
clinical practice, these factors are communicated with the
patient to choose the most appropriate therapy. However,
before a PET-guided treatment algorithm can be reliably
implemented, more research focusing on standardization of
protocols and inter-institutional technical differences
should be performed in larger patient cohorts.
To date, it is difﬁcult to compare results from different
institutes and more importantly, published cutoff values are
method speciﬁc and often institute speciﬁc, especially since
they are also affected by acquisition protocol, reconstruc-
tion algorithm, and region of interest deﬁnition.
61,62 Most
importantly, to overcome these problems large multicenter
prospective trials are necessary.
In conclusion, FDG-PET seems to be useful for prog-
nostication and (neo)adjuvant treatment response
assessment in esophageal cancer. However, more attention
has to be paid in standardization of FDG-PET acquisition
and reconstruction.
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